Lixte Biotechnology Holdings, Inc. Email Format

Biotechnology ResearchNew York, United States2-10 Employees

Lixte Biotechnology Holdings, Inc. is a small, publicly traded biotechnology company based in East Setauket, New York, focused on developing therapies for cancer. Its portfolio centers on inhibitors of protein phosphatases that regulate cell division and DNA damage repair, as well as inhibitors of protein deacetylases that influence gene expression and protein degradation. The lead compound LB-100 is in a Phase I trial and is described as potentially first-in-class. 

The company aims to augment existing cancer treatments, with phosphatase inhibitors expected to enhance the effectiveness of standard chemotherapy and radiation, and to be used in combination with other targeted therapies. Deacetylase inhibitors show anti-cancer activity in models and have potential applications beyond cancer, including certain inherited metabolic diseases and neurodegenerative conditions. In April 2026, Lixte announced preliminary results from a clinical trial combining LB-100 with Dostarlimab at the Society of Gynecologic Oncology conference in San Juan, Puerto Rico.

Sign up for free to view info

Company overview Employee directory